Dren Bio raises $350M to take its rare blood cancer antibody towards launch

Dren Bio has raised $350 million in an oversubscribed private financing to push its lead antibody, dibotatug, towards the market. The San Carlos, California company announced the round on 29 October. It was co-led by Juvia Group and Lightspeed Venture Partners.

Who put money in

New investors are Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management and OrbiMed. Returning backers include 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital and ArrowMark Partners. Sujal Shah, co-founder and managing director of Juvia Group, and Shelley Chu, a partner at Lightspeed, join the board.

Get The Biotech Brief every TuesdayThree-minute read. Free. One-click unsubscribe.

For scale, BioSpace notes that Dren's earlier rounds were a $60 million Series A in 2020 and a $65 million Series B in 2022. The company did not give this round a series letter.

The drug

Dibotatug (DR-01) is a fully human antibody against CD94. It is designed to remove the cytotoxic cells driving disease while leaving the rest of the immune system largely intact. The lead indications are cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, two rare blood cancers with no approved treatments. Dren says more than 300 patients have been dosed in its Phase 1/2 study, with high overall and complete response rates in relapsed or refractory disease. BioSpace reports that ClinicalTrials.gov lists a primary readout for December.

"It is rare to find novel science of this quality" Sujal Shah, co-founder and managing director, Juvia Group

Where the money goes

The round funds late-stage development, a regulatory submission and a planned commercial launch of dibotatug. It also pays for expansion into aplastic anaemia, other bone marrow failure syndromes and autoimmune disease, and for the rest of the pipeline. That includes programmes from Dren's myeloid engager and phagocytosis platform, whose lead programme, DR-0201, was acquired by Sanofi in May 2025 and is now SAR448501. DR-0202 is being evaluated in solid tumours.

The bigger picture

Dren, led by founder and CEO Nenad Tomasevic, has chosen a large private round to fund the path to a filing and a planned launch, rather than handing the asset to a partner. With a readout listed for December, the next few months will show whether the data support that plan.

What it means for hiring

Moving from a Phase 1/2 study to a filing and launch means building functions a research-led company may not yet have: regulatory affairs leadership, medical affairs, market access and a first commercial team.
Rare haematology launches depend on finding patients and the specialists who treat them. In our view, commercial and medical leaders with rare blood cancer launch experience will be in short supply.
Expansion into autoimmune disease and bone marrow failure adds clinical development work in new therapeutic areas, so we'd expect demand for clinical leads who can run studies outside oncology.

Share Ask Jordan about this →